Alexandria Real Estate Equities, Inc. (ARE) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

for Alexandria at this moment in time as the gold standard and leader of our niche. We invented and pioneered life science real estate, a whole new asset class and category, 31 years ago during the early years of the biotechnology revolution. Our North Star was and remains our focus on innovation clusters and ecosystems unique to the life science industry, different than almost every other property type. We're blessed with best assets, best tenants, best mega campus, and best team. Our relentless mission is driven by building the future of life-changing innovation and enabling the world's leading innovators to advance and better human health. The biotechnology revolution started almost 50 years ago, and in those 50 years, we've only been able to therapeutically address less than 10% of the more than 10,000 diseases known to humankind. No one lives in a family, community which has not been struck by the wrath of disease and illness, devastating in so many ways. We now find ourselves on the precipice of an entirely new age of discovery and innovation at the intersection of biology and technology 50 years later. Biology, it's important to remember, is inherently slow and complex. The life science industry, and particularly the innovation engine of the biotech sector, is mission critical for a strong, safe, healthier country and planet, as well as for America's global leadership, future economic growth and security. As opposed to most property types, office industrial and resi, we operate in a highly regulated industry that takes extraordinary time and cost to bring life-changing medicines to patients. To get a lifesaving product on the market, you only can sell that product for a handful of years in a regime of pricing oversight, sometimes control, different than other ...